Summarized by Masters of Longevity from Longevity Docs News.
Topline phase 3 results showed larger A1C and weight drops with retatrutide.
Key Takeaways
- Retatrutide lowered A1C by 2.2 points versus semaglutide's 1.8.
- Retatrutide produced about 20.9% weight loss versus 9.4% for semaglutide.
- Topline, open‑label data have not established definitive clinical effects.
